Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 2137 • ACR Convergence 2025
Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey
Francesco Baldo¹, Greta Rogani², Claudia Bracaglia³, Dirk Foell⁴, Marco Gattorno⁵, Jordi anton⁶, Paul Brogan⁷, Scott Canna⁸, randy Cron⁹, Alexiei GROM¹⁰, Merav Heshin Bekenstein¹¹, Raju Khubchandani¹², Seza Özen¹³, Pierre Quartier¹⁴, Angelo Ravelli¹⁵, Grant Schulert¹⁶, Mao Mizuta¹⁷, Joost Swart¹⁸, Rashmi Sinha¹⁹, AnnaCarin Horne²⁰, Fabrizio De Benedetti²¹, Christiaan Scott²², Marija Jelusic²³, Masaki Shimizu²⁴, Bruno Fautrel²⁵, Nicolino Ruperto²⁶, Sebastiaan Vastert² and Francesca Minoia²⁷, ¹ASST-Pini-CTO, Milano, Milan, Italy, ²University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, ³IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, ⁴Universisty Hospital of Muenster, Muenster, ⁵IRCCS G. Gaslini, Genova, Genoa, Italy, ⁶Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, ⁷UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Cincinnati Children’s Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ¹¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ¹²Jaslok Hospital and Research Center, Mumbai, India, ¹³Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁴Hôpital Necker-Enfants Malades, Paris, France, ¹⁵IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁷Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan, Kobe, Japan, ¹⁸Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ¹⁹Systemic JIA Foundation, Cincinnati, OH, ²⁰Karolinska University Hospital, Sollentuna, Sweden, ²¹Bambino Gesu Children's Hospital, Rome, Rome, Italy, ²²Childrens Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ²³University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ²⁴Tokyo Medical and Dental University, Bunkyo-ku, Kanazawa, Japan, ²⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁶Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ²⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: Despite continuous advances in care and the recent publication of updated international recommendations, relevant discrepancies in the management of Still’s disease (SD) may still…
Abstract Number: 1812 • ACR Convergence 2025
Inflammasome and UPR activation in monocytes of HLA B27 positive children with Enthesitis related arthritis category of JIA
Shivika Guleria¹ and Amita Aggarwal², ¹SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Enthesitis related arthritis (ERA) is a chronic immune-inflammatory disease with unknown etiology. HLA-B27 is the strongest risk factor predisposing to ERA like Spondyloarthritis (SpA).…
Abstract Number: 0427 • ACR Convergence 2025
Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
Vilde Øverlien Dåstøl¹, Kristine Løkås Haftorn², Maria Christine Magnus³, Sigrid Hestetun⁴, Siri Eldevik Håberg⁵, Lisa Rider⁶, Karen H. Costenbader⁷, Ida Henriette Caspersen⁸, Sjurdur Frodi Olsen⁹, Ketil Størdal¹⁰ and Helga Sanner¹, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ³Norwegian Institute of Public Health, Centre for Fertility and Health, Oslo, Norway, ⁴Oslo University Hospital, Department of Rheumatology/University of Oslo, Oslo, Norway, ⁵Norwegian Institute of Public Health, Centre for Fertility and Health/University of Bergen, Oslo, Norway, ⁶National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁷Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁸Norwegian Institute of Public Health, Centre for Fertility and Health/Oslo University Hospital, Oslo, Norway, ⁹Statens Serum Institut,Biobank, congenital disorders, and vaccines preparedness/Harvard T.H. Chan School of Public Health, Copenhagen, Denmark, ¹⁰Oslo University Hospital, Department of Pediatric and Adolescent Medicine/University of Oslo, Oslo, Norway
Background/Purpose: Maternal smoking during pregnancy has been associated with a seemingly lower risk of juvenile idiopathic arthritis (JIA) in the child (1), contrasting with smoking’s…
Abstract Number: 0406 • ACR Convergence 2025
Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Mariia Pavlenko², Mekibib Altaye³, Hermine Brunner⁴, Margaret Chang⁵, Ashley Cooper⁶, Stefanie Davidson⁷, Alexandra Duell⁴, Bharti Gangwani⁵, Aimee Hersh⁸, Gary Holland⁹, Carl Langefeld¹⁰, Melissa Lerman¹¹, Mindy Lo⁵, Virginia Miraldi Utz⁴, Sampath Prahalad¹², Grant Schulert⁴, Megan Quinlan-Waters¹³, Erin Stahl⁶, Edmund Tsui⁹ and Sheila Angeles-Han¹⁴, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Boston Children's Hospital, Boston, MA, ⁶Children's Mercy Kansas City, Kansas City, MO, ⁷Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, ⁸University of Utah, Salt Lake City, UT, ⁹UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, ¹⁰Wake Forest University School of Medicine, Winston Salem, NC, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Emory + Children's Pediatric Institute, Atlanta, GA, ¹³Cincinnati Children's Hospital Medical Center, CCHMC, ¹⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Chronic anterior uveitis (CAU) develops in 15-20% of juvenile idiopathic arthritis (JIA) cases. Early detection may prevent vision loss. However, known clinical risk factors…
Abstract Number: 0028 • ACR Convergence 2025
Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes
Adam He¹, Hannah Ainsworth², Kaiyu Jiang³, Ekaterina Khtovatkova², Yanmin Chen³, Carl Langefeld⁴, Charles G Danko¹ and James N. Jarvis⁵, ¹Cornell University Baker School of Veterinary Medicine, Ithaca, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Wake Forest University School of Medicine, Winston Salem, NC, ⁵University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Multiple genomic regions are known to confer risk for JIA. However, identifying the SNPs that exert the biological effects that confer risk, and therefore…
Abstract Number: 2134 • ACR Convergence 2025
Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort
Eileen Rife¹, Lexi Auld², Guihua Zhai³, Esraa Eloseily⁴, Grant Schulert⁵ and Yukiko Kimura⁶, ¹University of Alabama at Birmingham, birmingham, AL, ²Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ³UAB, Birmingham, ⁴UT Southwestern Children's Medical Center, Dallas, TX, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Children with Systemic Juvenile Idiopathic Arthritis (SJIA) who develop lung disease (LD) are at significantly increased risk of serious complications and even death. Early…
Abstract Number: 1811 • ACR Convergence 2025
Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Mariana Correia Marques¹, Michael Matt², Sophia Chou³, Peter Burbelo⁴, Zuoming Deng⁵, George Tomlinson⁶, Yukiko Kimura⁷, Grant Schulert² and Michael Ombrello⁸, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Rockville, MD, ⁴Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, ⁵Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶University of Toronto, Toronto, ON, Canada, ⁷Hackensack Meridian School of Medicine, New York, NY, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Interleukin (IL)-1 inhibitors are now regarded as the first line treatment option for systemic juvenile idiopathic arthritis (sJIA), however in up to half of…
Abstract Number: 0424 • ACR Convergence 2025
Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India
Sreelekha Kambhampati¹, keerthi vardhan yerram², Kavitha Meesala¹, Phani Kumar Devarasetti² and Liza rajasekhar³, ¹Nizams institute of medical sciences, hyderabad, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic arthritis in children, but its diagnosis is often challenging due to overlapping symptoms with other…
Abstract Number: 0404 • ACR Convergence 2025
Disease Extension in Children with Limited Juvenile Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Eveline Wu¹, Stephen Balevic², Angel Marks³, Manjushri Bhapkar⁴, Baoshan Zhang³, Alex Fist⁴, Melanie Kohlheim⁵, Vincent Del Gaizo⁶, Laine Thomas³ and Laura Schanberg⁷, ¹UNC Chapel Hill, Chapel Hill, NC, ²Department of Pediatrics, Duke University, Durham, ³Department of Biostatistics & Bioinformatics, Duke University, Durham, ⁴Duke Clinical Research Institute, Duke University, Durham, ⁵CARRA, Granville, OH, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁷Duke University Medical Center, DURHAM, NC
Background/Purpose: For children with limited juvenile idiopathic arthritis (JIA), defined as ≤4 affected joints and without uveitis, psoriasis, or sacroiliitis at presentation, it is unknown…
Abstract Number: 2135 • ACR Convergence 2025
Medication Use and Disease Activity in Systemic Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Christina Gulla¹, Mary Beth Son², Tara Lozy³, Yukiko Kimura⁴ and Ginger Janow⁵, ¹Hackensack University Medical Center, Hackensack, NJ, ²Boston Children's Hospital, Boston, MA, ³Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, ⁴Hackensack Meridian School of Medicine, New York, NY, ⁵Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ
Background/Purpose: Historically, treatment for systemic juvenile idiopathic arthritis (sJIA) included high dose glucocorticoids (GC) and conventional systemic (cs) disease modifying anti-rheumatic drugs (DMARDs) with significant…
Abstract Number: 1810 • ACR Convergence 2025
Destabilized Treg Cells Predominant in Severe Forms of Juvenile Idiopathic Arthritis
Ki Pui Lam¹, Claudia Harris², Jennifer Cheng³, Lwiza AitDowd⁴, Maryam Ashoor⁵, Ahmad Bakhsh³, Carrie Bryant³, Siobhan Case⁶, Mia Chandler³, Joyce Chang³, Ezra Cohen⁷, Fatma Dedeoglu³, Olha Halyabar⁸, Jonathan Hausmann⁹, Melissa Hazen³, Sonia Iosim¹⁰, Liyoung Kim¹¹, Jeffrey Lo³, Mindy Lo³, Emma Materne³, Esra Meidan¹², Megan Perron¹³, Helene Powers¹⁰, Mary Beth Son³, Holly Wobma³, Margaret Chang³, Pui Lee¹⁴, Peter Nigrovic¹¹ and Lauren Henderson¹⁵, ¹Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, ²Division of Immunology, Boston Childrens Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Brookline, MA, ⁶UpToDate, Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁷Bmc, NEEDHAM, MA, ⁸Children's Hospital/Boston Medical Center, Newton, MA, ⁹Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ¹⁰Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, ¹¹Boston Children's Hospital, Brookline, MA, ¹²Boston Children's Hospital, Somerville, MA, ¹³Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Natick, MA, ¹⁴Boston Children's Hospital, Newton, MA, ¹⁵Boston Children's Hospital, Watertown, MA
Background/Purpose: T peripheral helper (Tph) cells stimulate excessive B cell responses in the joints of patients with autoantibody-positive arthritis, including seropositive RA in adults and…
Abstract Number: 0425 • ACR Convergence 2025
High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease
Tahnee Spoden¹, Samira Nazzar Romero², Deborah McCurdy³, Alice Hoftman⁴, Sangmee Bae⁵, Jennifer Wang⁴, Ani Shahbazian⁴ and Christina Charles-Schoeman⁶, ¹UCLA, Los Angeles, CA, ²Nemours Children's Health, Orlando, ³UCLA Medical Center, Los Angeles, CA, ⁴UCLA, Los Angeles, ⁵UCLA Rheumatology, Los Angeles, CA, ⁶UCLA Medical Center, Santa Monica, CA
Background/Purpose: Cardiovascular disease remains the leading cause of mortality in patients with Rheumatoid Arthritis (RA). Normally, high density lipoprotein (HDL) acts in a cardioprotective capacity…
Abstract Number: 0405 • ACR Convergence 2025
Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study
Hermine Brunner¹, Ivan Foeldvari², Gerd Horneff³, Antonio Mera Varela⁴, Angelo Ravelli⁵, Sharonjeet Kaur⁶, Swapnil Suhas Dahale⁷, Ruvie Martin⁸, Daniel Lovell¹, Alberto Martini⁹ and Nicolino Ruperto¹⁰, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, ³Asklepios Klinik, Hamburg, Germany, ⁴Rheumatology Division. Hospital Clínico Universitario de Santiago and Instituto de Investigaciones Sanitarias (IDIS), School of Medicine, Santiago de Compostela, Spain, ⁵IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷IQVIA, Mumbai, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Università di Genova, Genova, Italy, ¹⁰Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy
Background/Purpose: Secukinumab demonstrated efficacy and safety in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), for up to…
Abstract Number: 2132 • ACR Convergence 2025
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
Ayah Eltoum¹, Eileen Rife², Livie Timmerman³, Emily Smitherman⁴, Melissa Mannion⁴ and John Bridges⁵, ¹University of Alabama at Birmingham, Hoover, AL, ²University of Alabama Birmingham, Vestavia Hills, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL
Background/Purpose: The transition from pediatric to adult-oriented rheumatology care is a critical period for young adults with childhood-onset rheumatic diseases. The Bridge to Adult Care…
Abstract Number: 1809 • ACR Convergence 2025
Mass Spectrometry-Based N-Terminomics Uncovers Proteolytic Signatures and Pathways in Juvenile Idiopathic Arthritis Synovial Fluid
Andrew Zeft¹, Sirada Panupattanapong², Laura Nedorezov³, Sumit Bhutada³ and Suneel Apte³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic disease marked by persistent synovial inflammation, often leading to structural joint damage. While numerous proteases produced by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].